Study protocol to investigate the efficacy of confocal laser endomicroscopy-based selective single-elimination diet over standard fivefold elimination diet in patients with endomicroscopically proven food intolerance : app-assisted, monocentric, double-blind, randomised and controlled trial in Germany

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..

INTRODUCTION: Imprecise nutritional recommendations due to a lack of diagnostic test accuracy are a frequent problem for individuals with adverse reactions to foods but no precise diagnosis. Consequently, patients follow very broad and strict elimination diets to avoid uncontrolled symptoms such as diarrhoea and abdominal pain. Dietary limitations and the uncertainty of developing gastrointestinal symptoms after the inadvertent ingestion of food have been demonstrated to reduce the quality of life (QoL) of affected individuals and subsequently might increase the risk of malnutrition and intestinal dysbiosis. This trial aims to investigate the effects of a tailored diet based on the confocal laser endoscopy (CLE) examination result to limit the side effects of unspecific and broad elimination diets and to increase the patient's QoL.

METHODS AND ANALYSIS: The study is designed as a prospective, double-blind, monocentric, randomised and controlled trial conducted at the University Hospital of Schleswig-Holstein, Campus Lübeck, Germany. One hundred seventy-two patients with non-IgE-related food allergies and positive CLE results will be randomised to either a tailored diet or a standard fivefold elimination diet. The primary endpoints are the difference between the end and the start of the intervention in health-related QoL and the sum score of the severity of symptoms after 12 weeks. Key secondary endpoints are changes in the severity of symptoms, further QoL measurements, self-assessed state of health and number of days with a pathologically altered stool. Microbiome diversity and metabolome of stool, urine and blood will also be investigated. Safety endpoints are body composition, body mass index and adverse events.

ETHICS AND DISSEMINATION: The study protocol was accepted by the ethical committee of the University of Lübeck (AZ: 22-111) on 4 May2022. Results of the study will be published in peer-reviewed journals and presented at scientific meetings.

TRIAL REGISTRATION NUMBER: German Clinical Trials Register (DRKS00029323).

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:13

Enthalten in:

BMJ open - 13(2023), 11 vom: 02. Nov., Seite e072024

Sprache:

Englisch

Beteiligte Personen:

Heßler, Nicole [VerfasserIn]
Kordowski, Anna [VerfasserIn]
Sasse, Jill [VerfasserIn]
Ahlemann, Greta [VerfasserIn]
Schulz, Franziska [VerfasserIn]
Schröder, Torsten [VerfasserIn]
Exner, Anna [VerfasserIn]
Jablonski, Lennart [VerfasserIn]
Jappe, Uta [VerfasserIn]
Bischoff, Stephan C [VerfasserIn]
Grzegorzek, Marcin [VerfasserIn]
König, Inke R [VerfasserIn]
Sina, Christian [VerfasserIn]

Links:

Volltext

Themen:

Clinical Trial Protocol
Endoscopy
GASTROENTEROLOGY
Irritable Bowel Syndrome
Journal Article
NUTRITION & DIETETICS
Research Support, Non-U.S. Gov't

Anmerkungen:

Date Completed 06.11.2023

Date Revised 08.11.2023

published: Electronic

DRKS: DRKS00029323

Citation Status MEDLINE

doi:

10.1136/bmjopen-2023-072024

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM364108045